NEW YORK (GenomeWeb News) – Nuclea Biotechnologies this week announced Immuno-Biological Laboratories will be the primary US distributor of Nuclea's HER-2/neu kits.

Nuclea and IBL also will coordinate joint marketing efforts for the serum HER-2/neu kits as part of the deal.

The microtiter-based test measures the level of HER-2/neu in serum and is used to monitor metastatic breast cancer. Based in Minneapolis, IBL distributes diagnostic assays for autoimmunity, endocrinology, infectious disease, oncology, and neuroscience. It also offers laboratory services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.

May
04
Sponsored by
Qiagen

This online seminar will provide an overview of the use of liquid biopsies for cancer recurrence monitoring with a particular focus on colorectal cancer.

May
11
Sponsored by
PerkinElmer

This webinar will provide an overview of an RNA-seq protocol that has been optimized to study small RNA species such as microRNAs.

May
23
Sponsored by
Agilent Technologies

This webinar will discuss a target enrichment workflow for high-confidence detection of variants. 

Jun
20
Sponsored by
OmniSeq

This webinar will discuss RNA sequencing as an alternative to immunohistochemistry (IHC) in selecting patients for cancer immunotherapy.